TrialAntimicrobial agents and chemotherapy2000

Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260).

L M Demeter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.